WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
1. (WO2012103276) COMBINATIONS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2012/103276    International Application No.:    PCT/US2012/022638
Publication Date: 02.08.2012 International Filing Date: 26.01.2012
A61K 31/4439 (2006.01)
Applicants: GLAXOSMITHKLINE INTELLECTUAL PROPERTY LIMITED [GB/GB]; 980 Great West Road Brentford, Middlesex TW8 9GS (GB) (For All Designated States Except US).
BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM [US/US]; 201 West 7th Street Austin, TX 78701 (US) (For All Designated States Except US).
AUGER, Kurt R. [US/US]; (US) (For US Only).
BOTTSFORD-MILLER, Justin [US/US]; (US) (For US Only).
SOOD, Anil K. [US/US]; (US) (For US Only)
Inventors: AUGER, Kurt R.; (US).
SOOD, Anil K.; (US)
Agent: PENG, Tony W.; Glaxosmithkline Global Patents, UW2220 709 Swedeland Road, P.O.Box 1539 King Of Prussia, PA 19406-0939 (US)
Priority Data:
61/436,435 26.01.2011 US
Abstract: front page image
(EN)The present invention relates to a method of treating ovarian cancer in a female human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a ovarian cancer treatment method that includes administering 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2- pyrimidinyl]amino]-2-methylbenzenesulfonamide, or a pharmaceutically acceptable salt thereof, and 2-[(5-chloro-2-[[3-methyl-1-(1-methylethyl)-1 H-pyrazol-5-yl]amino]-4- pyridinyl)amino]-N-methoxybenzamide, or a pharmaceutically acceptable salt thereof, and optionally 1,7β,10β-trihydroxy-9-oxo-5β,20-epoxytax-11-ene-2α,4, 13α-triyl 4- acetate 2-benzoate 13-{(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3- phenylpropanoate}, to a human in need thereof.
(FR)La présente invention concerne un procédé de traitement du cancer des ovaires chez une femme et des associations pharmaceutiques utiles dans ledit traitement. En particulier, le procédé concerne un procédé de traitement du cancer des ovaires qui consiste à administrer du 5-[[4-[(2,3-diméthyl-2H-indazol-6-yl)méthylamino]-2- pyrimidinyl]amino]-2-méthylbenzènesulfonamide, ou son sel pharmaceutiquement acceptable, et du 2-[(5-chloro-2-[[3-méthyl-1-(1-méthyléthyl)-1 H-pyrazol-5-yl]amino]-4- pyridinyl)amino]-N-méthoxybenzamide, ou son sel pharmaceutiquement acceptable, et facultativement du 1,7β,10β-trihydroxy-9-oxo-5β,20-époxytax-11-ène-2α,4, 13α-triyl 4- acétate 2-benzoate 13-{(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3- phénylpropanoate}, à une femme en ayant besoin.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)